Value Creation Since Seed
In the 16 months since closing the seed round (Q4 2024), Legit.Health has built the platform required for accelerated growth: a commercial team, new tier-1 customer logos, additional regulatory certifications, scientific output, captured grants, and operational maturity. Top-line revenue undershot the optimistic 2024 budget, but every foundational asset that drives the next phase is now in place.
The honest acknowledgement
The 2024 business plan projected €789K revenue for 2024. Actual: €411K. The 2025 budget projected revenue acceleration; actual was €604K. Top-line was below the optimistic plan in both years.
What we learned: B2B clinical AI sales cycles are 6-12 months for hospital/insurance and 9-12 months per study for pharma. The 2024 plan assumed faster cycles. Deals are not lost, they are in motion and closing at higher TCV than originally planned as multi-year framework agreements replace single-study contracts.
What did move forward (the value created)
1. Senior team built and renewed
At seed close (Q4 2024), the company had 23 employees with a founder-dependent sales motion. As of April 2026, headcount stands at 26 employees + 2 co-founders without payroll (Gerardo CTO, Antonio CMO) for 28 effective team members. The +3 net headcount dramatically understates the qualitative transformation: 9 new hires + 1 internal promotion + 7 rotations resulted in a renewed senior layer.
Senior renewal moment (Mar 2025 + Mar/Apr 2026)
Three of the four senior non-founder roles were renewed in coordinated moves: Sales Director (Giuseppe), Quality Manager (Saray) and Legal Director (Alejandra), plus the first international senior hire (Chris McKee in UK).
Additional new hires post-seed (5 specialists + 1 internal promotion)
★ The key strategic point ─────────────────────
The Mar 2025 senior renewal of three functions (Sales + Quality + Legal) within a single week is a coordinated management execution, not opportunistic hiring. The Apr 2026 addition of Chris McKee (UK Sales Director) demonstrates the renewal is still active, not a one-off event.
See the Key Senior Team page for detailed profiles of the 6 senior non-founders (Ignacio + Alba + Giuseppe + Saray + Alejandra + Chris).
─────────────────────────────────────────────────
Net result: from a founder-dependent sales motion to a structured 6-person commercial team + 2-person CS team, with renewed senior leadership across Sales, Quality/Regulatory, and Legal. This is what allowed billings to grow +145% YoY even with the longer-than-planned sales cycles.
2. New tier-1 customer logos won
3. New certifications (regulatory + security)
★ Insight on ENS Alto ─── ──────────────────────
Why ENS Alto matters strategically: Spanish public health administrations (SESPA, SERMAS, CCAA health systems) cannot legally contract a digital health solution without ENS Alto certification. Most early-stage healthtech startups don't have it because the certification process is intense (Spanish Centro Criptológico Nacional audit, full information security management system). Having it pre-Series A unlocks immediately a procurement channel that competitors cannot access.
─────────────────────────────────────────────────
4. Awards & external validation since seed
Three external recognitions awarded to Legit.Health in the post-seed period, each from a distinct institutional context: a national innovation ranking, a sectoral health award, and an export-promotion impact award.
★ Insight on award diversity ─────────────────
The post-seed awards each come from a different institutional source: ICEX/Red.es (export + digital agency, commercial signal), Lideremos (private health-sector network, sectoral signal), ENISA + Foro ADR (national innovation finance ecosystem, innovation signal). Three different validators in three different contexts = breadth of external endorsement, not a single ecosystem clapping for itself.
─────────────────────────────────────────────────
5. New scientific publications + active pipeline
Since seed close, 3 new peer-reviewed papers published (AGPPGA 2026, APASI 2025, Head & Neck 2025), bringing the total to 7. On top of that, 2 papers formally accepted (publishing Q2 2026) and 8 additional papers in active pipeline (submission and drafting stages).
Pipeline forecast: 10 additional publications by EoY 2027
| Status | Count | Detail |
|---|---|---|
| ✅ Accepted (Q2 2026 publication) | 2 | ALADIN (Acne) · Surface area measurement |
| 🔵 Under review | 4 | GPP severity device · DIQA cross-domain · GPP diagnostic accuracy · Melanoma early detection |
| ✏️ Drafting | 4 | DDI dataset limitations · AWOSI (Wound) · AVASI (Vitiligo) · Real-world Sanitas elderly homes |
| Total forthcoming | 10 | Publishing 2026-2027 |
★ Insight ─────────────────────────────────────
Cumulative scientific output trajectory:
- At seed close (Q4 2024): 4 papers published
- Today (May 2026): 7 papers published (+3 since seed)
- Forecast EoY 2026: 9-10 papers (2 accepted Q2 + 1-2 from under-review)
- Forecast EoY 2027: 15-17 papers (full pipeline executed)
For a healthtech company at this stage, producing 10 peer-reviewed publications in 18 months is exceptional output. Each paper validates a distinct algorithm + pathology, unlocking a new pharma trial channel and a new use case for hospitals/insurance. The pipeline is the clinical evidence engine that competitors cannot replicate in less than 3-5 years of catch-up investment.
─────────────────────────────────────────────────
See full pipeline detail in Product → Clinical Evidence.
6. Non-dilutive capital captured since seed
| Grant | Institution | Amount | Status |
|---|---|---|---|
| Zabaldu 2024 | Gobierno Vasco / SPRI | €23,614 | ✅ Captured |
| Zabaldu 2025 | Gobierno Vasco / SPRI | €48,005 | ✅ Captured |
| EPIC-X 2026 | EIC / EU | €60,000 | ✅ Captured |
| ICEX Next 2025 | ICEX | €24,000 | ✅ Captured |
| Internacionalización Germany | DFB | €50,905 | ✅ Captured |
| Internacionalización UK | DFB | €37,360 | ✅ Captured |
| Internacionalización US | DFB | €46,253 | ✅ Captured |
| Fast Track Innobideak 2026 (aEASI) | SPRI Gobierno Vasco | €250,000 | ⏳ Submitted 30/04/2026, resolution by 31/10/2026 |
| RED.IA Salud (VALIDERMIA) | Red.es | €400-600K | ⏳ Submitted, pending resolution |
| Plan 2i 2026 (VALIDERMIA) | DFB | ~€97K | ⏳ Submitted, pending resolution |
| Subtotal captured | €290K+ | ||
| Subtotal pending | €747-947K |
★ Insight ─────────────────────────────────────
Why this matters for the investor pushback: while ARR was growing 2x, the team was also raising €290K of non-dilutive capital, plus another €747-947K pending resolution (Fast Track Innobideak aEASI €250K, RED.IA Salud €400-600K, Plan 2i 2026 €97K). That's effectively another seed round in expected non-dilutive capital since Q4 2024. Most early-stage operators can't sustain commercial growth AND grant capture at this volume.
─────────────────────────────────────────────────
7. Operational maturity built
8. Team headcount evolution
| Metric | Q4 2024 (seed close) | Apr 2026 | Δ |
|---|---|---|---|
| Employees on payroll | 23 | 26 | +3 |
| Co-founders (Gerardo, Antonio · non-payroll) | +2 | +2 | — |
| Total effective team | 25 | 28 | +3 |
The 9 new hires + 1 internal promotion + 7 rotations net to only +3 employees, which understates the qualitative transformation. The senior renewal pattern delivered upgraded leadership in Sales (Giuseppe), Quality/Regulatory (Saray), Legal (Alejandra), with the UK Sales Director (Chris McKee) opening international presence — all without inflating headcount.
★ Insight for investors ─────────────────────────
The capital discipline reading: most early-stage companies "scale" their team by 30-50% post-seed. Legit.Health grew net +13% in headcount but upgraded the seniority of three function leads simultaneously. That's the signature of a CEO who is buying capability per euro, not headcount per euro. For a Series A investor evaluating burn multiple and capital efficiency, this is a measurable positive signal that deserves explicit recognition.
─────────────────────────────────────────────────
9. Capital efficiency: internal execution vs outsourcing
A core principle of the post-seed period: build internal capability, don't rent it. Functions that early-stage startups typically outsource at high markup were brought in-house at senior level, preserving runway while creating durable capability.
Cost discipline: spent less than budgeted
The combined effect of internal execution + senior renewal without headcount inflation produced actual costs below budget in 2025:
- 2025 budget for personnel + external services: planned for higher spend
- 2025 actuals: below plan, primarily because functions were brought in-house instead of outsourced at consultant rates
- Result: same operational capability at lower euros, extending runway and improving capital efficiency
★ Why this matters for the bridge case ── ───────
A frequent investor objection to bridge rounds is: "if you spent the seed efficiently, why do you need more capital?" The answer here is specific: the bridge funds acceleration (commercial expansion + FDA + clinical validation US), not maintenance. The historical record of spending discipline (below budget, in-house over outsourced, senior renewal at flat headcount) is the proof that the bridge euros will be used as efficiently as the seed euros. The internal-execution pattern is the credibility marker.
─────────────────────────────────────────────────
10. The compounding effect (now visible)
The combination of all of the above is what produces the ARR doubling that VCs ask for as a metric. None of this is one-off; each asset compounds:
The reframe
The question is not "did revenue hit the 2024 business plan?" Revenue didn't, because the plan assumed faster sales cycles than B2B clinical AI actually allows.
The question is: "Is the company in a materially stronger position than 16 months ago, with a credible path to €1M ARR?"
The answer is unambiguously yes. ARR doubled. Commercial muscle built. New regulatory jurisdictions captured. 9 new tier-1 logos including ICON, Lux Med BUPA, SESPA, Sagimet, Novartis, Pierre Fabre, CUF, CHU Rennes, plus J&J expansion. €290K+ non-dilutive captured. 2 new peer-reviewed papers. FDA pathway opened.
The bridge round funds the conversion of all this latent value into the €1M ARR that unlocks Series A.
See also
- Key Senior Team: detailed profiles of the 6 senior non-founders (Ignacio, Alba, Giuseppe, Saray, Alejandra, Chris)
- Bridge Thesis: why a bridge round, what it unlocks
- Path to €1M ARR: from current state to €1M ARR
- ARR & Revenue Mix: foundational metrics
- Funding: full capital raised + grant detail